{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:47:48Z","timestamp":1793533668174,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Surgery"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.asjsur.2024.02.113","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T16:11:15Z","timestamp":1709568675000},"page":"4260-4270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The safety and efficacy of NOACs versus LMWH for thromboprophylaxis after THA or TKA: A systemic review and meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Kai","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.asjsur.2024.02.113_bib1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2106\/00004623-200704000-00012","article-title":"Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030","volume":"89","author":"Kurtz","year":"2007","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.asjsur.2024.02.113_bib2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.2022.13416","article-title":"Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial","volume":"328","author":"Sidhu","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.asjsur.2024.02.113_bib3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.asjsur.2024.02.113_bib4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH07-03-0212","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen","year":"2007","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib5","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.asjsur.2024.02.113_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13018-021-02902-8","article-title":"Incidence and risk factors associated with preoperative deep venous thrombosis in the young and middle-aged patients after hip fracture","volume":"17","author":"Ding","year":"2022","journal-title":"J\u00a0Orthop Surg Res"},{"key":"10.1016\/j.asjsur.2024.02.113_bib7","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.jvs.2009.01.058","article-title":"Call to action to prevent venous thromboembolism","volume":"49","author":"Wakefield","year":"2009","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.asjsur.2024.02.113_bib8","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1055\/s-0039-1693460","article-title":"Rivaroxaban versus aspirin in prevention of venous thromboembolism: a meta-analysis of 9 randomized controlled trials comprising 7,656 patients","volume":"119","author":"Xie","year":"2019","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/j.1875-9114.2012.01106.x","article-title":"Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis","volume":"32","author":"Sobieraj","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.asjsur.2024.02.113_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1160\/TH10-02-0142","article-title":"Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study","volume":"104","author":"Raskob","year":"2010","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1345\/aph.1M681","article-title":"Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery","volume":"44","author":"Melillo","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.asjsur.2024.02.113_bib12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0883-5403(97)90064-4","article-title":"Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty","volume":"12","author":"Lieberman","year":"1997","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1016\/j.asjsur.2024.02.113_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1160\/TH09-07-0434","article-title":"New oral anticoagulants in development","volume":"103","author":"Weitz","year":"2010","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib14","series-title":"VA Evidence-Based Synthesis Program Reports. Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement","author":"Adam","year":"2012"},{"key":"10.1016\/j.asjsur.2024.02.113_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-156-10-201205150-00421","article-title":"Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis","volume":"156","author":"Neumann","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep23726","article-title":"Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"6","author":"Ning","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.asjsur.2024.02.113_bib17","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1159\/000479840","article-title":"Effectiveness and tolerability of anticoagulants for thromboprophylaxis after major joint surgery: a network meta-analysis","volume":"42","author":"Wang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.asjsur.2024.02.113_bib18","first-page":"1489","article-title":"Clinical factors and recurrent venous thrombotic events","volume":"294","author":"Flansbaum","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.asjsur.2024.02.113_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/107602960601200201","article-title":"Hereditary and acquired thrombophilic disorders","volume":"12","author":"Bick","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.asjsur.2024.02.113_bib20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0002-9149(00)00766-9","article-title":"Risk of pulmonary embolism and\/or deep venous thrombosis in Asian-Americans","volume":"85","author":"Klatsky","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.asjsur.2024.02.113_bib21","doi-asserted-by":"crossref","first-page":"1220.e1217","DOI":"10.1016\/j.amjmed.2017.05.026","article-title":"Do factor V leiden and prothrombin G20210A mutations predict recurrent venous thromboembolism in older patients?","volume":"130","author":"M\u00e9an","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","article-title":"Factor V leiden thrombophilia","volume":"13","author":"Kujovich","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.asjsur.2024.02.113_bib25","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib26","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A\u00a0new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib28","first-page":"4077","article-title":"Efficacy and safety of rivaroxaban in preventing deep venous thromboembolism after major orthopedic operations","volume":"9","author":"Chen","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A\u00a0randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib30","first-page":"292","article-title":"Dabigatran versus Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized clinical trial","volume":"10","author":"Mirdamadi","year":"2014","journal-title":"ARYA Atheroscl"},{"key":"10.1016\/j.asjsur.2024.02.113_bib31","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib33","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib34","first-page":"11","article-title":"The efficacy and safety of rivaroxaban in preventing deep vein thrombosis after hip replacement","author":"Dang","year":"2020","journal-title":"Indian J Pharmaceut Sci"},{"key":"10.1016\/j.asjsur.2024.02.113_bib35","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib36","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.asjsur.2024.02.113_bib38","first-page":"704","article-title":"Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: a pilot study","volume":"23","author":"Xie","year":"2017","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"key":"10.1016\/j.asjsur.2024.02.113_bib39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II\u2217). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3923\/ijp.2018.1.8","article-title":"Comparing the efficacy, safety and cost of the anticoagulants: rivaroxaban and nadroparin in hip replacement surgery","volume":"14","author":"Jiang","year":"2017","journal-title":"Int J Pharmacol"},{"key":"10.1016\/j.asjsur.2024.02.113_bib41","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A\u00a0once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement","volume":"114","author":"Eriksson","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.asjsur.2024.02.113_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12959-015-0057-x","article-title":"Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: stars J-V","volume":"13","author":"Fuji","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.asjsur.2024.02.113_bib43","article-title":"Incidence of silent venous thromboembolism after total hip arthroplasty: a comparison of rivaroxaban and enoxaparin","volume":"28","author":"Rahman","year":"2020","journal-title":"J\u00a0Orthop Surg"},{"key":"10.1016\/j.asjsur.2024.02.113_bib44","first-page":"68","article-title":"A\u00a0randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Gretler","year":"2017","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/th15-07-0527","article-title":"Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty","volume":"115","author":"Kim","year":"2016","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib46","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/MBC.0000000000000121","article-title":"Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty","volume":"25","author":"Zou","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib47","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3349\/ymj.2019.60.7.626","article-title":"Comparison of apixaban and low molecular weight heparin in preventing deep venous thrombosis after total knee arthroplasty in older adults","volume":"60","author":"Jiang","year":"2019","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.asjsur.2024.02.113_bib48","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.arth.2014.05.029","article-title":"Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan","volume":"29","author":"Fuji","year":"2014","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1016\/j.asjsur.2024.02.113_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Committee","year":"2009","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1016\/j.asjsur.2024.02.113_bib50","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","article-title":"Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"120","author":"Eriksson","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.asjsur.2024.02.113_bib51","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)","volume":"8","author":"Eriksson","year":"2010","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib52","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.asjsur.2024.02.113_bib53","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"134","author":"Fuji","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.asjsur.2024.02.113_bib54","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.asjsur.2024.02.113_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040336","article-title":"Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study","volume":"11","author":"van der Veen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.asjsur.2024.02.113_bib56","first-page":"2303","article-title":"Rivaroxaban and low molecular heparin in prevention of deep venous thrombosis and blood loss after total hip arthroplasty in elderly patients","volume":"22","author":"Yun-fei","year":"2018","journal-title":"Chinese J Tissue Eng Resc"},{"key":"10.1016\/j.asjsur.2024.02.113_bib57","first-page":"56","article-title":"Clinical comparison of rivaroxaban and low molecular weight heparin in prevention of lower extremity deep vein thrombosis after joint replacement in elderly patients with knee osteoarthritis","volume":"16","author":"Jianwei","year":"2019","journal-title":"Northern Pharm"},{"key":"10.1016\/j.asjsur.2024.02.113_bib58","first-page":"377","article-title":"Prevention of deep vein thrombosis after total joint replacement by rivaroxaban","volume":"34","author":"Shuying","year":"2018","journal-title":"Pharm J Chin PLA"},{"key":"10.1016\/j.asjsur.2024.02.113_bib59","first-page":"35","article-title":"Rivaroxaban combined with nursing intervention for preventing deep vein thrombosis of joint replacement surgery in 79 cases","volume":"24","author":"Xuemei","year":"2015","journal-title":"China Pharm"},{"key":"10.1016\/j.asjsur.2024.02.113_bib60","first-page":"2023","article-title":"Different anticoagulant drugs during knee joint replacement: changes of hemorheology","volume":"19","author":"Yong","year":"2015","journal-title":"Chinese J Tissue Eng Resc"},{"key":"10.1016\/j.asjsur.2024.02.113_bib61","first-page":"57","article-title":"Efficacy and safety evaluation of rivaroxaban versus enoxaparin for prevention of deep vein thrombosis after joint replacement","volume":"15","author":"Qingjiang","year":"2017","journal-title":"Chinese Foreign Med Res"},{"key":"10.1016\/j.asjsur.2024.02.113_bib62","first-page":"20","article-title":"Clinical observation the prevention of femoral neck fracture arthroplasty postoperative thrombosis with rivaroxaban","volume":"20","author":"Limiao","year":"2014","journal-title":"Chinese J Throm Hemosc"},{"key":"10.1016\/j.asjsur.2024.02.113_bib63","first-page":"619","article-title":"Prospective controlled study of rivaroxaban on prevention of deep venous thrombosis after joint arthroplasty","volume":"24","author":"Zhigang","year":"2016","journal-title":"Orthop J China,"},{"key":"10.1016\/j.asjsur.2024.02.113_bib64","first-page":"1148","article-title":"Rivaroxaban and low molecular weight heparin calcium to prevent deep vein thrombosis after artificial joint replacement","volume":"17","author":"Kaifang","year":"2011","journal-title":"Chin J Rehabil Theory Pract"},{"key":"10.1016\/j.asjsur.2024.02.113_bib65","first-page":"5440","article-title":"Efficacy and safety of rivaroxaban in the prevention of deep vein thrombosis after hip arthroplasty","volume":"17","author":"Hui","year":"2013","journal-title":"Chinese J Tissue Eng Resc"},{"key":"10.1016\/j.asjsur.2024.02.113_bib66","first-page":"61","article-title":"Clinical effect of Rivaroxaban tablet and low molecular weight heparin calcium injection on prevention of lower extremity deep vein thrombosis after senile joint replacement","volume":"25","author":"Pengwei","year":"2018","journal-title":"Capital Food Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib67","first-page":"226","article-title":"Clinical observation of rivaroxaban for prevention of deep vein thrombosis after artificial joint replacement","volume":"22","author":"Shuchao","year":"2013","journal-title":"Henan Med Res"},{"key":"10.1016\/j.asjsur.2024.02.113_bib68","first-page":"6","article-title":"Pharmacological analysis and clinical application research of rivaroxaban in prevention of deep venous.hrombosis after artificial joint replacement","volume":"10","author":"Zhuyan","year":"2015","journal-title":"China Prac Med"},{"key":"10.1016\/j.asjsur.2024.02.113_bib69","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/phar.1133","article-title":"Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery","volume":"32","author":"Mahan","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.asjsur.2024.02.113_bib70","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In\u00a0vitro and in\u00a0vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib71","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.arth.2013.02.016","article-title":"Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty","volume":"28","author":"Russell","year":"2013","journal-title":"J\u00a0Arthroplasty"},{"key":"10.1016\/j.asjsur.2024.02.113_bib72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.asjsur.2024.02.113_bib73","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12891-018-2215-3","article-title":"Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis","volume":"19","author":"Lu","year":"2018","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.asjsur.2024.02.113_bib74","doi-asserted-by":"crossref","first-page":"e3675","DOI":"10.1136\/bmj.e3675","article-title":"Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons","volume":"344","author":"G\u00f3mez-Outes","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.asjsur.2024.02.113_bib75","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCOUTCOMES.110.957712","article-title":"Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials","volume":"3","author":"Huisman","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.asjsur.2024.02.113_bib76","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1378\/chest.12-2634","article-title":"Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison","volume":"144","author":"Kwok","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.asjsur.2024.02.113_bib77","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/1076029611404215","article-title":"Preventing venous thromboembolism following orthopedic surgery in the United States: impact of special populations on clinical outcomes","volume":"17","author":"Deitelzweig","year":"2011","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Asian Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1015958424003750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1015958424003750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:08:03Z","timestamp":1730977683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1015958424003750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1015958424003750"],"URL":"https:\/\/doi.org\/10.1016\/j.asjsur.2024.02.113","relation":{},"ISSN":["1015-9584"],"issn-type":[{"value":"1015-9584","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of NOACs versus LMWH for thromboprophylaxis after THA or TKA: A systemic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.asjsur.2024.02.113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Asian Surgical Association and Taiwan Society of Coloproctology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}